ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer, with robust commercial traction—FY25 revenue reached ~$113 million, up 700% YoY. Key pipeline catalysts include upcoming trial readouts in bladder cancer and glioblastoma; positive data could drive further upside, but valuation is highly sensitive to setbacks.
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenström non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.
ImmunityBio: Why I Am Upgrading To A Buy For 2026
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but losses remain heavy and commercial traction is not yet spectacular. Anktiva shows superior duration of response versus competitors and promising survival data in NSCLC, supporting long-term revenue potential.
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs
ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter runway, though net debt remains high at $603 million. The company's robust adoption underpins current valuation; future growth hinges on expanding indications and successful clinical trial readouts.
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-Hodgkin lymphoma, and a new Phase II trial for long COVID. Despite bullish long-term outlook, near-term risks include ongoing losses, potential dilution, regulatory hurdles, and manufacturing dependencies.
ImmunityBio: A Small Bet Is Warranted
ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up sales post-J-code but faces competition from JNJ's TAR-200 and regulatory setbacks. Promising early data from the t-haNK program and expanding pipeline support the investment thesis for IBRX.
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
